Fresh off a phase 3 win in biliary tract cancer, Akeso CEO Michelle Xia, Ph.D., is touting the PD-1xVEGF bispecific antibody ivonescimab’s ability beyond non-small cell lung cancer, even as she continues to defend the drug’s data against skepticism.
Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula
Resonate Group, an ambitious Nigerian indigenous company with global aspirations, that aligns her vision with strategic intent to provide innovative solutions and services in Oil & Gas, Maritime, Manufacturing, Finance, Steel, Healthcare, and Supply Chain sectors of the Nigerian economy...
Copyright 2024 - All Rights Reserved By Resonate Group | Designed By Nysut Digital Studios